Perkenalan
Halaman ini memberikan analisis komprehensif tentang riwayat insider trading yang diketahui di Ted W Love. Insider adalah pejabat, direktur, atau investor penting dalam suatu perusahaan. Adalah ilegal bagi insider untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik dan non-publik. Hal ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan ke SEC melalui Formulir 4. Meskipun ada pembatasan ini, penelitian akademis menunjukkan bahwa insider – secara umum – cenderung mengungguli pasar di perusahaan mereka sendiri.
Profitabilitas Perdagangan Rata-rata
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari seluruh pembelian pasar terbuka yang dilakukan oleh insider dalam 3 tahun terakhir. Untuk menghitungnya, kami memeriksa setiap pembelian pasar terbuka dan tidak terencana yang dilakukan oleh insider, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata perdagangan tersebut selama 3, 6, dan 12 bulan, merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami menghitung rata-rata semua metrik kinerja untuk menghitung metrik kinerja bagi insider. Daftar ini hanya mencakup insider yang telah melakukan setidaknya tiga perdagangan dalam 2 tahun terakhir.
Jika profitabilitas perdagangan insider ini adalah "T/A", maka insider tersebut belum melakukan pembelian di pasar terbuka dalam 3 tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang dapat diandalkan.
Frekuensi Pembaruan: Harian
Perusahaan dengan Posisi Insider yang Dilaporkan
Pengajuan SEC menunjukkan Ted W Love telah melaporkan kepemilikan atau perdagangan di perusahaan berikut:
| Keamanan | Judul | Kepemilikan Terbaru yang Dilaporkan |
|---|---|---|
| US:GILD / Gilead Sciences, Inc. | Director | 5.484 |
| US:JAZZ / Jazz Pharmaceuticals plc | Director | 1.527 |
| US:RPRX / Royalty Pharma plc | Director | 53.848 |
| US:SGEN / Seagen Inc | Director | 0 |
| US:GBT / Global Blood Therapeutics Inc. | President and CEO, Director | 0 |
| Director | 0 | |
| US:FOLD / Amicus Therapeutics, Inc. | Director | 18.574 |
| US:CASC / Cascadian Therapeutics, Inc. | Director | 0 |
| US:KBIO / KaloBios Pharmaceuticals, Inc. | Director | 5.000 |
| US:SNTS / Santarus, Inc | Director | 0 |
| US:MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF | Director | 62.451 |
| US:ONXX / Onyx Pharmaceuticals Inc | EVP, R&D and Tech. Operations | 77.756 |
| US:AFFY / Affymax, Inc. | Director | 12.000 |
| US:ABIO / ARCA biopharma, Inc. | Director | 7.500 |
Bagaimana Menafsirkan Grafik
Bagan berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka dan tidak terencana yang dilakukan oleh Ted W Love. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham dipetakan sebagai persentase perubahan kumulatif harga saham. Misalnya, jika perdagangan insider dilakukan pada tanggal 1 Januari 2019, grafik akan menunjukkan persentase perubahan harian sekuritas hingga hari ini. Jika harga saham naik dari $10 menjadi $15 selama waktu ini, persentase perubahan harga saham kumulatif akan menjadi 50%. Perubahan harga dari $10 menjadi $20 adalah 100%, dan perubahan harga dari $10 menjadi $5 adalah -50%.
Pada akhirnya, kami mencoba untuk menentukan seberapa dekat korelasi perdagangan insider dengan keuntungan berlebih (positif atau negatif) pada harga saham untuk melihat apakah insider mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi insider. Pertimbangkan situasi di mana insider melakukan hal ini. Dalam situasi ini, kita mengharapkan (a) keuntungan positif setelah pembelian, atau (b) keuntungan negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, yang menunjukkan keuntungan positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, yang menunjukkan keuntungan negatif setelah setiap transaksi penjualan.
Namun, hal ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam kenaikan non-siklus selama bertahun-tahun, maka kita perkirakan semua lahan pasca pembelian akan miring ke atas. Demikian pula, penurunan non-siklus selama bertahun-tahun akan mengakibatkan penurunan pasca-perdagangan. Tak satu pun dari grafik ini menunjukkan aktivitas insider trading.
Indikator terkuat adalah situasi di mana harga saham sangat bersiklus, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat memberi isyarat kepada insider yang mengatur waktu perdagangan demi keuntungan finansial mereka.
Pembelian Insider AFFY / Affymax, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AFFY / Affymax, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider AFFY / Affymax, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AFFY / Affymax, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AFFY / Affymax, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AFFY / Affymax, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider RPRX / Royalty Pharma plc - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada AFFY / Affymax, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider RPRX / Royalty Pharma plc - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di AFFY / Affymax, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Riwayat Insider Trading
Tabel ini menunjukkan daftar lengkap perdagangan insider yang dilakukan oleh Ted W Love sebagaimana diungkapkan kepada Securities Exchange Commission (SEC).
| Tanggal Berkas | Tanggal Trans | Formulir | Kode | Keamanan | Kode | Saham | Sisa Saham | Persen Mengubah |
Saham Harga |
Trans Nilai |
Tersisa Nilai |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 |
|
4 | GILD |
GILEAD SCIENCES, INC.
Common Stock |
A - Award | 1.146 | 5.484 | 26,42 | ||||
| 2026-03-02 |
|
4 | JAZZ |
Jazz Pharmaceuticals plc
Ordinary Shares |
A - Award | 1.527 | 1.527 | |||||
| 2025-05-14 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 7.614 | 53.848 | 16,47 | ||||
| 2025-05-08 |
|
4 | GILD |
GILEAD SCIENCES, INC.
Common Stock |
A - Award | 1.516 | 4.338 | 53,72 | ||||
| 2024-06-10 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 9.293 | 46.234 | 25,16 | ||||
| 2024-05-09 |
|
4 | GILD |
GILEAD SCIENCES, INC.
Common Stock |
A - Award | 2.310 | 2.822 | 451,17 | ||||
| 2024-02-06 |
|
4 | GILD |
GILEAD SCIENCES, INC.
Common Stock |
A - Award | 512 | 512 | |||||
| 2023-12-15 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | -4.255 | 0 | -100,00 | 229,00 | -974.395 | ||
| 2023-06-26 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 7.747 | 36.941 | 26,54 | ||||
| 2023-06-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 2.044 | 6.748 | 43,45 | ||||
| 2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -2.500 | 0 | -100,00 | ||||
| 2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -2.500 | 0 | -100,00 | ||||
| 2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -102.000 | 0 | -100,00 | ||||
| 2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -119.650 | 0 | -100,00 | ||||
| 2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -119.650 | 0 | -100,00 | ||||
| 2022-10-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -576.318 | 0 | -100,00 | ||||
| 2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 18.291 | 576.318 | 3,28 | 16,40 | 299.972 | 9.451.615 | |
| 2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | 17.650 | 119.650 | 17,30 | ||||
| 2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | 17.650 | 119.650 | 17,30 | ||||
| 2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | -35.300 | 558.027 | -5,95 | ||||
| 2022-09-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | -221.200 | 593.327 | -27,16 | ||||
| 2022-09-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -9.200 | 814.527 | -1,12 | 68,15 | -626.980 | 55.510.015 | |
| 2022-09-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 9.109 | 823.727 | 1,12 | ||||
| 2022-09-06 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 9.444 | 814.618 | 1,17 | ||||
| 2022-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -10.018 | 805.174 | -1,23 | 32,40 | -324.583 | 26.087.638 | |
| 2022-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 20.205 | 815.192 | 2,54 | ||||
| 2022-06-24 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 6.328 | 29.194 | 27,67 | ||||
| 2022-05-17 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
A - Award | 3.676 | 3.676 | |||||
| 2022-05-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1.503 | 4.704 | 46,95 | ||||
| 2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to buy) |
A - Award | 118.090 | 118.090 | |||||
| 2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 72.877 | 72.877 | |||||
| 2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 72.877 | 72.877 | |||||
| 2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.445 | 56.667 | -14,29 | ||||
| 2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -4.074 | 794.987 | -0,51 | 29,87 | -121.690 | 23.746.262 | |
| 2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 9.445 | 799.061 | 1,20 | ||||
| 2022-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 839 | 789.616 | 0,11 | 25,37 | 21.285 | 20.032.558 | |
| 2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 35.820 | -20,00 | ||||
| 2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 22.500 | -33,33 | ||||
| 2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 0 | -100,00 | ||||
| 2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -10.531 | 788.777 | -1,32 | 29,33 | -308.874 | 23.134.829 | |
| 2022-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 29.955 | 799.308 | 3,89 | ||||
| 2022-01-06 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -24.821 | 1.117.815 | -2,17 | 3,40 | -84.391 | 3.800.571 | |
| 2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 44.775 | -16,67 | ||||
| 2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 33.750 | -25,00 | ||||
| 2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 9.750 | -50,00 | ||||
| 2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -14.853 | 789.413 | -1,85 | 27,33 | -405.932 | 21.574.657 | |
| 2021-09-24 |
|
4/A | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 29.955 | 804.266 | 3,87 | ||||
| 2021-09-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.444 | 66.112 | -12,50 | ||||
| 2021-09-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -4.683 | 794.174 | -0,59 | 29,85 | -139.788 | 23.706.094 | |
| 2021-09-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 9.444 | 798.857 | 1,20 | ||||
| 2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 44.775 | -16,67 | ||||
| 2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 33.750 | -25,00 | ||||
| 2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 9.750 | -50,00 | ||||
| 2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -14.853 | 789.413 | -1,85 | 27,33 | -405.932 | 21.574.657 | |
| 2021-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 29.955 | 804.266 | 3,87 | ||||
| 2021-06-29 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 5.726 | 22.866 | 33,41 | ||||
| 2021-05-18 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
A - Award | 3.462 | 3.462 | |||||
| 2021-05-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1.402 | 3.201 | 77,93 | ||||
| 2021-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 75.556 | 75.556 | |||||
| 2021-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 132.433 | 132.433 | |||||
| 2021-03-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 370 | 774.311 | 0,05 | 36,21 | 13.398 | 28.037.801 | |
| 2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 53.730 | -14,29 | ||||
| 2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 45.000 | -20,00 | ||||
| 2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 19.500 | -33,33 | ||||
| 2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.063 | 0 | -100,00 | ||||
| 2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.893 | 773.941 | -2,26 | 49,49 | -885.525 | 38.302.340 | |
| 2021-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 42.018 | 791.834 | 5,60 | ||||
| 2020-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 4.460 | 4.460 | |||||
| 2020-08-18 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 1.799 | 1.799 | |||||
| 2020-08-17 |
|
4 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
A - Award | 7.280 | 17.280 | 72,80 | ||||
| 2020-08-10 | 3 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
20.000 | ||||||||
| 2020-08-10 | 3 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
20.000 | ||||||||
| 2020-08-10 | 3 | RPRX |
Royalty Pharma plc
Class A Ordinary Shares |
20.000 | ||||||||
| 2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -8.955 | 62.685 | -12,50 | ||||
| 2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 56.250 | -16,67 | ||||
| 2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 29.250 | -25,00 | ||||
| 2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.062 | 12.063 | -50,00 | ||||
| 2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -20.834 | 749.816 | -2,70 | 67,48 | -1.405.878 | 50.597.584 | |
| 2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 42.017 | 770.650 | 5,77 | ||||
| 2020-08-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
G - Gift | -306.000 | 728.633 | -29,58 | ||||
| 2020-07-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -14.812 | 0 | -100,00 | ||||
| 2020-07-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -11.377 | 0 | -100,00 | 0,06 | -683 | ||
| 2020-07-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Restricted Stock Units |
D - Sale to Issuer | -15.575 | 0 | -100,00 | 18,00 | -280.350 | ||
| 2020-06-15 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 11.377 | 11.377 | |||||
| 2020-06-15 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
A - Award | 7.281 | 15.575 | 87,79 | ||||
| 2020-06-08 |
|
4 | FOLD |
AMICUS THERAPEUTICS, INC.
Stock Options (right to buy) |
A - Award | 18.574 | 18.574 | |||||
| 2020-06-08 |
|
4 | FOLD |
AMICUS THERAPEUTICS, INC.
Common Stock |
A - Award | 5.855 | 131.000 | 4,68 | ||||
| 2020-06-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 141.400 | 141.400 | |||||
| 2020-04-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -40.000 | 1.034.633 | -3,72 | 80,00 | -3.200.160 | 82.774.779 |
| 2020-04-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.517 | 1.074.633 | -0,14 | 80,63 | -122.320 | 86.650.560 |
| 2020-04-29 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.300 | 1.076.150 | -0,12 | 81,15 | -105.494 | 87.328.712 |
| 2020-02-20 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.818 | 1.077.450 | -0,17 | 70,92 | -128.940 | 76.416.956 |
| 2020-02-20 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -2.189 | 1.079.268 | -0,20 | 70,22 | -153.721 | 75.790.732 |
| 2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 114.190 | 114.190 | |||||
| 2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 71.640 | 71.640 | |||||
| 2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 67.500 | -14,29 | ||||
| 2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 39.000 | -20,00 | ||||
| 2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.063 | 24.125 | -33,33 | ||||
| 2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -14.169 | 1.081.457 | -1,29 | 65,26 | -924.669 | 70.575.884 | |
| 2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 33.063 | 1.095.626 | 3,11 | ||||
| 2020-02-04 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 579 | 1.062.563 | 0,05 | 36,68 | 21.238 | 38.974.811 | |
| 2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -1.031 | 1.061.984 | -0,10 | 82,45 | -85.011 | 87.565.785 |
| 2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -32.150 | 1.063.015 | -2,94 | 81,85 | -2.631.600 | 87.011.817 |
| 2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.819 | 1.095.165 | -0,62 | 81,01 | -552.436 | 88.723.916 |
| 2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -523 | 1.101.984 | -0,05 | 83,56 | -43.703 | 92.083.436 |
| 2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -10.166 | 1.102.507 | -0,91 | 82,78 | -841.562 | 91.267.734 |
| 2020-01-23 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -29.311 | 1.112.673 | -2,57 | 81,98 | -2.402.837 | 91.213.928 |
| 2019-12-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -87.500 | 0 | -100,00 | ||||
| 2019-12-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -43.383 | 1.141.984 | -3,66 | 76,88 | -3.335.285 | 87.795.730 | |
| 2019-12-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 87.500 | 1.185.367 | 7,97 | ||||
| 2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -3.716 | 1.097.867 | -0,34 | 76,15 | -282.973 | 83.602.572 |
| 2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -23.152 | 1.101.583 | -2,06 | 77,72 | -1.799.327 | 85.612.828 |
| 2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.800 | 1.124.735 | -0,60 | 76,78 | -522.122 | 86.360.078 |
| 2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.332 | 1.131.535 | -0,56 | 75,73 | -479.512 | 85.689.222 |
| 2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.750 | 1.137.867 | -0,59 | 75,39 | -508.873 | 85.782.200 |
| 2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -8.525 | 1.144.617 | -0,74 | 74,66 | -636.478 | 85.457.334 |
| 2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -996 | 1.153.142 | -0,09 | 74,08 | -73.784 | 85.424.759 |
| 2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -12.442 | 1.154.138 | -1,07 | 75,35 | -937.475 | 86.961.528 |
| 2019-12-09 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
S - Sale | X | -11.287 | 1.166.580 | -0,96 | 74,62 | -842.262 | 87.052.883 |
| 2019-10-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 14.812 | 14.812 | |||||
| 2019-10-02 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
A - Award | 8.294 | 8.294 | |||||
| 2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -11.250 | 78.750 | -12,50 | ||||
| 2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 48.750 | -16,67 | ||||
| 2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.062 | 36.188 | -25,00 | ||||
| 2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -16.394 | 1.177.867 | -1,37 | 54,25 | -889.374 | 63.899.285 | |
| 2019-08-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 33.062 | 1.194.261 | 2,85 | ||||
| 2019-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS, INC.
Stock Options (right to buy) |
A - Award | 19.473 | 19.473 | |||||
| 2019-07-01 |
|
4 | FOLD |
AMICUS THERAPEUTICS, INC.
Common Stock |
A - Award | 6.250 | 125.145 | 5,26 | ||||
| 2019-04-10 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 87.500 | -28,57 | ||||
| 2019-04-10 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.354 | 1.161.199 | -1,47 | 58,51 | -1.015.383 | 67.941.753 | |
| 2019-04-10 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.178.553 | 3,06 | ||||
| 2019-04-10 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 579 | 1.143.553 | 0,05 | 36,68 | 21.238 | 41.945.524 | |
| 2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 58.500 | -14,29 | ||||
| 2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.063 | 48.250 | -20,00 | ||||
| 2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 90.000 | 90.000 | |||||
| 2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 145.000 | 145.000 | |||||
| 2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -7.814 | 1.142.974 | -0,68 | 48,44 | -378.510 | 55.365.661 | |
| 2019-02-05 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 21.813 | 1.150.788 | 1,93 | ||||
| 2018-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -9.750 | 68.250 | -12,50 | ||||
| 2018-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.062 | 60.313 | -16,67 | ||||
| 2018-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -10.816 | 1.128.975 | -0,95 | 43,15 | -466.710 | 48.715.271 | |
| 2018-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 21.812 | 1.139.791 | 1,95 | ||||
| 2018-07-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
M - Exercise | -12.194 | 132.806 | -8,41 | ||||
| 2018-07-17 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 12.194 | 1.117.979 | 1,10 | 16,40 | 199.982 | 18.334.856 | |
| 2018-06-11 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 8.912 | 8.912 | |||||
| 2018-06-11 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 3.081 | 8.895 | 52,99 | ||||
| 2018-03-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Stock Units |
D - Sale to Issuer | -13.927 | 0 | -100,00 | ||||
| 2018-03-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
U - Other | -37.394 | 0 | -100,00 | ||||
| 2018-02-16 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 122.500 | -22,22 | ||||
| 2018-02-16 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.353 | 1.105.785 | -1,55 | 62,30 | -1.081.092 | 68.890.406 | |
| 2018-02-16 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.123.138 | 3,22 | ||||
| 2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 78.000 | 78.000 | |||||
| 2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 122.000 | 122.000 | |||||
| 2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.063 | 72.375 | -14,29 | ||||
| 2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -5.981 | 1.087.142 | -0,55 | 59,60 | -356.468 | 64.793.663 | |
| 2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 12.063 | 1.093.123 | 1,12 | ||||
| 2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 157.500 | -18,18 | ||||
| 2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.353 | 1.081.060 | -1,58 | 57,90 | -1.004.739 | 62.593.374 | |
| 2018-02-02 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.098.413 | 3,29 | ||||
| 2018-01-26 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 192.500 | -15,38 | ||||
| 2018-01-26 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.354 | 1.063.413 | -1,61 | 58,15 | -1.009.135 | 61.837.466 | |
| 2018-01-26 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.080.767 | 3,35 | ||||
| 2018-01-18 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -35.000 | 227.500 | -13,33 | ||||
| 2018-01-18 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -17.083 | 1.045.767 | -1,61 | 52,10 | -890.024 | 54.484.461 | |
| 2018-01-18 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 35.000 | 1.062.850 | 3,41 | ||||
| 2017-09-26 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
M - Exercise | -2.375 | 0 | -100,00 | ||||
| 2017-09-26 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
F - Taxes | -594 | 37.394 | -1,56 | 3,94 | -2.340 | 147.332 | |
| 2017-09-26 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
M - Exercise | 2.375 | 37.988 | 6,67 | ||||
| 2017-08-14 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | -262.500 | 262.500 | -50,00 | ||||
| 2017-08-14 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -124.106 | 1.027.850 | -10,77 | 3,40 | -421.340 | 3.489.551 | |
| 2017-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | -12.062 | 84.438 | -12,50 | ||||
| 2017-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
F - Taxes | -4.533 | 1.151.956 | -0,39 | 25,10 | -113.778 | 28.914.096 | |
| 2017-08-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
M - Exercise | 12.062 | 1.156.489 | 1,05 | ||||
| 2017-06-27 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
M - Exercise | -9.058 | 0 | -100,00 | ||||
| 2017-06-27 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
F - Taxes | -2.265 | 35.613 | -5,98 | 3,78 | -8.562 | 134.617 | |
| 2017-06-27 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
M - Exercise | 9.058 | 37.878 | 31,43 | ||||
| 2017-06-16 |
|
4/A | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 5.814 | 147.814 | 4,09 | ||||
| 2017-06-15 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 16.236 | 16.236 | |||||
| 2017-06-15 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 5.814 | 5.814 | |||||
| 2017-06-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
M - Exercise | -2.148 | 0 | -100,00 | ||||
| 2017-06-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
F - Taxes | -537 | 28.820 | -1,83 | 3,34 | -1.794 | 96.259 | |
| 2017-06-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
M - Exercise | 2.148 | 29.357 | 7,89 | ||||
| 2017-06-13 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
A - Award | 13.927 | 13.927 | |||||
| 2017-02-14 |
|
5 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 1.413 | 1.144.427 | 0,12 | 13,73 | 19.400 | 15.712.983 | |
| 2017-02-14 |
|
5 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 378 | 1.143.014 | 0,03 | 15,20 | 5.746 | 17.373.813 | |
| 2017-02-10 |
|
5 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
M - Exercise | -2.723 | 0 | -100,00 | ||||
| 2017-02-10 |
|
5 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
F - Taxes | -681 | 27.209 | -2,44 | 7,38 | -5.026 | 200.802 | |
| 2017-02-10 |
|
5 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
M - Exercise | 2.723 | 27.890 | 10,82 | ||||
| 2017-02-03 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Common Stock |
P - Purchase | 23.000 | 27.209 | 546,45 | 4,24 | 97.520 | 115.366 | |
| 2017-01-19 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 145.000 | 145.000 | |||||
| 2017-01-19 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Restricted Stock Units |
A - Award | 96.500 | 96.500 | |||||
| 2016-12-16 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -24.821 | 1.139.815 | -2,13 | 3,40 | -84.391 | 3.875.371 | |
| 2016-06-28 |
|
4 | CASC |
Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU) |
A - Award | 54.347 | 54.347 | |||||
| 2016-06-13 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 20.000 | 20.000 | |||||
| 2016-02-03 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
A - Award | 1.925 | 1.142.636 | 0,17 | 16,09 | 30.973 | 18.385.013 | |
| 2016-01-07 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
P - Purchase | 2.500 | 2.500 | 20,00 | 50.000 | 50.000 | ||
| 2016-01-07 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
P - Purchase | 2.500 | 2.500 | 20,00 | 50.000 | 50.000 | ||
| 2016-01-07 |
|
4 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
P - Purchase | 5.000 | 1.140.711 | 0,44 | 20,00 | 100.000 | 22.814.220 | |
| 2015-09-28 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
A - Award | 14.245 | 14.245 | |||||
| 2015-09-09 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
M - Exercise | -17.341 | 0 | -100,00 | ||||
| 2015-09-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
F - Taxes | -4.336 | 13.005 | -25,00 | 3,25 | -14.092 | 42.266 | |
| 2015-09-09 |
|
4 | ONTY |
Oncothyreon Inc.
Common Stock |
M - Exercise | 17.341 | 17.341 | |||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.157.139 | ||||||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.849.996 | ||||||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.337.139 | ||||||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.234.996 | ||||||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.234.996 | ||||||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.157.139 | ||||||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.849.996 | ||||||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.337.139 | ||||||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.234.996 | ||||||||
| 2015-08-11 | 3 | GBT |
Global Blood Therapeutics, Inc.
Common Stock |
1.234.996 | ||||||||
| 2015-07-14 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 5.000 | 5.000 | |||||
| 2015-06-16 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
A - Award | 12.886 | 12.886 | |||||
| 2015-06-12 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 20.000 | 20.000 | |||||
| 2014-12-15 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 32.000 | 142.000 | 29,09 | 7,83 | 250.637 | 1.112.201 | |
| 2014-06-20 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 20.000 | 20.000 | |||||
| 2014-06-16 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 15.000 | 15.000 | |||||
| 2014-06-10 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
A - Award | 16.339 | 16.339 | |||||
| 2014-03-12 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Common Stock |
A - Award | 110.000 | 110.000 | 2,21 | 243.100 | 243.100 | ||
| 2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -35.000 | 0 | -100,00 | 26,76 | -936.600 | ||
| 2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -32.500 | 0 | -100,00 | 25,27 | -821.275 | ||
| 2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -34.500 | 0 | -100,00 | 26,68 | -920.460 | ||
| 2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -32.000 | 0 | -100,00 | 28,67 | -917.440 | ||
| 2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -34.500 | 0 | -100,00 | 28,88 | -996.360 | ||
| 2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -34.500 | 0 | -100,00 | 25,27 | -871.815 | ||
| 2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
D - Sale to Issuer | -34.500 | 0 | -100,00 | 10,07 | -347.415 | ||
| 2014-01-06 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
U - Other | -335.500 | 0 | -100,00 | 32,00 | -10.736.000 | ||
| 2013-09-06 |
|
4 | ONTY |
Oncothyreon Inc.
Restricted Share Unit (RSU) |
A - Award | 17.341 | 17.341 | |||||
| 2013-09-06 | 3 | ONTY |
Oncothyreon Inc.
Common Stock |
0 | ||||||||
| 2013-06-21 |
|
4 | MSTX |
Mast Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 62.451 | 62.451 | |||||
| 2013-06-17 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Options (right to buy) |
A - Award | 15.000 | 15.000 | |||||
| 2013-06-12 |
|
4 | SNTS |
SANTARUS INC
Stock Option (right to buy) |
A - Award | 34.500 | 34.500 | |||||
| 2013-05-02 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
| 2012-12-19 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
P - Purchase | 185.000 | 335.500 | 122,92 | 10,88 | 2.012.800 | 3.650.240 | |
| 2012-09-07 |
|
4 | ANX |
ADVENTRX PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 14.171 | 14.171 | |||||
| 2012-09-07 |
|
4 | ANX |
ADVENTRX PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 18.895 | 18.895 | |||||
| 2012-07-27 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5.241 | 77.756 | -6,31 | 73,97 | -387.687 | 5.751.759 |
| 2012-06-18 |
|
4 | AFFY |
AFFYMAX INC
Stock Option (Right to Buy) |
A - Award | 12.000 | 12.000 | |||||
| 2012-06-15 |
|
4 | FOLD |
AMICUS THERAPEUTICS INC
Stock Option (right to buy) |
A - Award | 30.000 | 30.000 | |||||
| 2012-06-14 |
|
4 | SNTS |
SANTARUS INC
Stock Option (right to buy) |
A - Award | 34.500 | 34.500 | |||||
| 2012-04-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | X | -757 | 82.997 | -0,90 | 36,58 | -27.689 | 3.035.831 |
| 2012-04-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 49.700 | 49.700 | |||||
| 2012-04-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
A - Award | 17.150 | 83.754 | 25,75 | ||||
| 2012-04-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
A - Award | 9.800 | 66.604 | 17,25 | ||||
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -34.500 | 0 | -100,00 | ||||
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -34.500 | 0 | -100,00 | ||||
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -34.500 | 0 | -100,00 | ||||
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -32.000 | 0 | -100,00 | ||||
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Stock Options (right to buy) |
M - Exercise | -15.000 | 0 | -100,00 | ||||
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 34.500 | 150.500 | 29,74 | 2,47 | 85.215 | 371.735 | |
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 34.500 | 116.000 | 42,33 | 2,38 | 82.110 | 276.080 | |
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 32.000 | 81.500 | 64,65 | 1,18 | 37.760 | 96.170 | |
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 34.500 | 49.500 | 230,00 | 2,02 | 69.690 | 99.990 | |
| 2012-03-12 |
|
4 | SNTS |
SANTARUS INC
Common Stock |
M - Exercise | 15.000 | 15.000 | 3,00 | 45.000 | 45.000 | ||
| 2012-02-03 |
|
4 | ONXX |
ONYX PHARMACEUTICALS INC
Common Stock |
F - Taxes | -2.098 | 56.804 | -3,56 | 41,98 | -88.074 | 2.384.632 | |
| 2009-03-03 |
|
4 | ABIO |
ARCA biopharma, Inc.
Option to Purchase Common Stock |
A - Award | 7.500 | 7.500 |
